Latest revenue
$2.8M
as of 2026-03-31
Latest net income
$-23.0M
as of 2026-03-31
Net margin
-814.1%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ALGS is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $209.6M
- Enterprise value
- $179.7M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 6.59×
- Dividend yield
- 0.0%
- 52-wk high
- $13.69
- 52-wk low
- $4.80
- Beta
- —
- Shares out
- 42.6M
5-year trend
What this company does
Item 1. Business. Overview We are a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections (e.g., SARS‑CoV‑2, SARS‑CoV, MERS‑CoV, and other related infections). The Aligos team has a demonstrated track record of success in drug development and medicinal chemistry in liver and viral diseases, resulting in three potential best‑in‑class drug candidates. Our pipeline of drug candidates includes pevifoscorvir sodium (previously known as…
AI summary unavailable — showing raw filing excerpt
Generated from ALGS's filing dated 2026-03-05
Key risks
k Factors. Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of…
AI summary unavailable — showing raw filing excerpt
Generated from ALGS's filing dated 2026-03-05
Profitability
Operating margin
-4024.9%
63.0%Net margin
-1106.7%
69.5%Return on equity
-45.2%
110.0%Return on assets
-27.3%
85.4%Leverage
Debt / equity
0.65×
119.1%Long-term debt / equity
0.00×
100.0%Debt / assets
39.5%
72.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $2.8M | +810.0% | $-23.0M | -153.5% | -814.1% |
Q4 2025 2025-12-31 | $910.0K | -69.7% | $-47.1M | +42.7% | -5176.5% |
Q3 2025 2025-09-30 | $0 | -100.0% | $-4.3M | +77.6% | — |
Q2 2025 2025-06-30 | $965.0K | +230.5% | $-15.9M | -413.4% | -1643.8% |
Q1 2025 2025-03-31 | $311.0K | +6.5% | $43.1M | +223.6% | 13854.7% |
Q4 2024 2024-12-31 | $3.0M | — | $-82.2M | — | -2731.1% |
Q3 2024 2024-09-30 | $19.0K | -98.2% | $-19.3M | -6.8% | -101363.2% |
Q2 2024 2024-06-30 | $292.0K | -88.7% | $5.1M | +126.9% | 1733.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on ALGS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ALGS
Institutional value
$2.3M
Total shares held
313.4K
Distinct holders
13
-27 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 178.3K | $1.3M | — | New |
| 2 | LPL Financial LLC | 51.5K | $382.6K | -14.5K (-22.0%) | Trimmed |
| 3 | UBS Group AG | 37.1K | $275.4K | +36.7K (+10081.6%) | Added |
| 4 | VANGUARD FIDUCIARY TRUST CO | 28.4K | $211.3K | — | New |
| 5 | BlackRock, Inc. | 13.0K | $96.9K | +0 (+0.0%) | No change |
| 6 | Golden State Wealth Management, LLC | 2.7K | $19.9K | +0 (+0.0%) | No change |
| 7 | Vanguard Global Advisers, LLC | 936 | $7.0K | — | New |
| 8 | WELLS FARGO & COMPANY/MN | 700 | $5.2K | -800 (-53.3%) | Trimmed |
| 9 | JPMORGAN CHASE & CO | 674 | $4.4K | +368 (+120.3%) | Added |
| 10 | Fortitude Family Office, LLC | 68 | $505 | — | New |
| 11 | SBI Securities Co., Ltd. | 26 | $193 | +0 (+0.0%) | No change |
| 12 | ELEVATION WEALTH PARTNERS, LLC | 4 | $30 | +0 (+0.0%) | No change |
| 13 | BNP PARIBAS FINANCIAL MARKETS | 3 | $22 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ALGS's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.